Fexapotide placebo crossover study reveals lower incidence of surgery

Nymox Pharmaceutical Corp. today announced the placebo crossover group from fexapotide Phase III trials received positive results.

Patients who were treated with a placebo and subsequently treated with fexapotide showed reduced surgery rates for enlarged prostate (BPH) and localized prostate cancer.

Three hundred and ninety-one men received double blind placebo injections during the initial Phase III study and crossed over to other treatments when the study was complete. The fexapotide patients required 82 percent to 95 percent fewer surgeries compared to patients who received conventional BPH treatments. The patients also saw a reduced rate of prostate cancer development.

“These exciting results from this long-term prospective analysis confirm what I and other researchers have consistently seen in the clinic — that it is obvious that fexapotide greatly helps patients in terms of symptomatic benefit for their BPH; and with these results, the clinical benefit also results in much less need for surgical intervention over the long-term," San Diego Clinical Trials Medical Director Dr. Mo Bidair said. "I believe these clinical results, combined with previously reported incidence and progression of prostate cancer in this patient population are truly important. Furthermore, the extreme safety of this new drug and the lack of sexual side effects are remarkably helpful for patients.”
Want to get notified whenever we write about Nymox Pharmaceutical Corporation ?
Next time we write about Nymox Pharmaceutical Corporation, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Nymox Pharmaceutical Corporation 777 Terrace Ave Hasbrouck Heights, NJ 07604